| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5645462 | Annals of Allergy, Asthma & Immunology | 2017 | 6 Pages |
Abstract
The estimated cost effectiveness of mepolizumab exceeds value thresholds. Achieving these thresholds would require significant discounts from the current list price. Alternatively, treatment limited to responders improves the cost effectiveness toward, but remains still slightly above, these thresholds. Payers interested in improving the efficiency of health care resources should consider negotiations of the mepolizumab price and ways to predict and assess the response to mepolizumab.
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
Melanie D. MS, R. Brett PhD, Daniel A. PhD, Jeffrey A. MD, Richard H. PhD, MS, Steven D. MD, MSc, Jonathan D. PhD,